Zacks Investment Research upgraded shares of Scpharmaceuticals (NASDAQ:SCPH) from a hold rating to a strong-buy rating in a report released on Wednesday, Zacks.com reports. Zacks Investment Research currently has $4.00 target price on the stock.
According to Zacks, “scPharmaceuticals, Inc., is a biopharmaceutical company. It engaged in developing pharmaceutical products for subcutaneous delivery. The Company’s pipeline programs include: scFurosemide lead product candidate, Furoscix, consists of its proprietary subcutaneous formulation of furosemide delivered via sc2Wear Infusor for diuresis in heart failure patients outside of the acute care setting. scPharmaceuticals, Inc., is based in BURLINGTON, United States. “
A number of other equities analysts have also recently weighed in on the stock. Leerink Swann cut shares of Scpharmaceuticals from an outperform rating to a market perform rating and lowered their price objective for the stock from $12.00 to $5.00 in a research report on Wednesday, January 30th. Svb Leerink cut shares of Scpharmaceuticals from an outperform rating to a market perform rating in a research report on Wednesday, January 30th. Three equities research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has an average rating of Buy and a consensus target price of $8.75.
NASDAQ:SCPH opened at $3.57 on Wednesday. The company has a debt-to-equity ratio of 0.10, a current ratio of 8.50 and a quick ratio of 8.50. The company has a market cap of $66.33 million, a P/E ratio of -2.25 and a beta of 1.31. Scpharmaceuticals has a fifty-two week low of $2.44 and a fifty-two week high of $14.36.
Scpharmaceuticals (NASDAQ:SCPH) last posted its quarterly earnings data on Wednesday, May 8th. The company reported ($0.47) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.52) by $0.05. As a group, equities analysts forecast that Scpharmaceuticals will post -2.02 EPS for the current year.
In other Scpharmaceuticals news, major shareholder Ra Capital Healthcare Fund Lp bought 389,862 shares of Scpharmaceuticals stock in a transaction on Thursday, April 11th. The shares were bought at an average cost of $2.70 per share, for a total transaction of $1,052,627.40. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 4.80% of the stock is owned by corporate insiders.
Institutional investors have recently added to or reduced their stakes in the business. SG Americas Securities LLC acquired a new stake in Scpharmaceuticals during the 1st quarter worth approximately $51,000. Jacobs Levy Equity Management Inc. acquired a new stake in Scpharmaceuticals during the 1st quarter worth approximately $71,000. Finally, BlackRock Inc. lifted its holdings in Scpharmaceuticals by 2.0% during the 4th quarter. BlackRock Inc. now owns 358,243 shares of the company’s stock worth $1,347,000 after buying an additional 7,094 shares in the last quarter. Institutional investors own 41.13% of the company’s stock.
Scpharmaceuticals Company Profile
scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is Furoscix that consists of proprietary subcutaneous formulation of furosemide, which is delivered through the SmartDose drug delivery system for treatment of congestion in decompensated heart failure patients outside of the acute care setting.
Read More: What are the most popular ETFs
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Scpharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scpharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.